Non-coding RNAs and Their Use in Cancer Diagnosis and Treatment

Abstract views: 55 / PDF downloads: 42


  • Hamid Ceylan Atatürk University


Cancer, Non-coding RNAs, MicroRNAs, Long Non-coding RNAs


Non-coding RNAs (ncRNAs) are non-protein-coding RNAs that are involved in important cellular processes as well as in the regulation of gene expression. In recent years, ncRNAs have been implicated in cancerization and have been found to be valuable biomarkers for cancer diagnosis and treatment. Therefore, understanding gene expression and other important cellular processes regulated by ncRNA networks can provide significant new insights into cancer biology and further lead to the development of new and effective therapeutic strategies. ncRNAs, especially microRNAs (miRNAs) and Long non-coding RNAs (lncRNAs), act as decoys to affect the binding of regulatory molecules to target genes. Therefore, these unique molecules can play a role in cancer by regulating genes involved in cell growth, apoptosis, and angiogenesis. In conclusion, ncRNAs hold great potential for cancer diagnosis and treatment. Further research into the specific functions and mechanisms of these molecules in cancer will lead to the development of more effective therapeutic and/or diagnostic approaches for cancer patients.

Author Biography

Hamid Ceylan, Atatürk University

Department of Molecular Biology and Genetics, Faculty of Science, Türkiye


D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-74, Mar 4 2011.

C. Zhang, C. Zhang, Q. Wang, Z. Li, J. Lin, and H. Wang, "Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types," JAMA Netw Open, vol. 3, no. 4, p. e202950, Apr 1 2020.

R. D. Neal et al., "Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review," Br J Cancer, vol. 112 Suppl 1, no. Suppl 1, pp. S92-107, Mar 31 2015.

S. Zhang, H. Xu, L. Zhang, and Y. Qiao, "Cervical cancer: Epidemiology, risk factors and screening," Chin J Cancer Res, vol. 32, no. 6, pp. 720-728, Dec 31 2020.

P. Le, G. Romano, P. Nana-Sinkam, and M. Acunzo, "Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer," Cancers (Basel), vol. 13, no. 6, Mar 18 2021.

F. Lai et al., "Activating RNAs associate with Mediator to enhance chromatin architecture and transcription," Nature, vol. 494, no. 7438, pp. 497-501, Feb 28 2013.

Y. Peng and C. M. Croce, "The role of MicroRNAs in human cancer," Signal Transduct Target Ther, vol. 1, p. 15004, 2016.

K. B. Reddy, "MicroRNA (miRNA) in cancer," Cancer Cell Int, vol. 15, p. 38, 2015.

C. A. Gebeshuber, K. Zatloukal, and J. Martinez, "miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis," EMBO Rep, vol. 10, no. 4, pp. 400-5, Apr 2009.

N. Yanaihara et al., "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis," Cancer Cell, vol. 9, no. 3, pp. 189-98, Mar 2006.

K. A. O'Donnell, E. A. Wentzel, K. I. Zeller, C. V. Dang, and J. T. Mendell, "c-Myc-regulated microRNAs modulate E2F1 expression," Nature, vol. 435, no. 7043, pp. 839-43, Jun 9 2005.

K. Otmani and P. Lewalle, "Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications," Front Oncol, vol. 11, p. 708765, 2021.

X. Qin, L. Yan, X. Zhao, C. Li, and Y. Fu, "microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer," Oncol Lett, vol. 4, no. 6, pp. 1290-1296, Dec 2012.

G. Misso et al., "Mir-34: a new weapon against cancer?," Mol Ther Nucleic Acids, vol. 3, no. 9, p. e194, Sep 23 2014.

J. J. Quinn and H. Y. Chang, "Unique features of long non-coding RNA biogenesis and function," Nat Rev Genet, vol. 17, no. 1, pp. 47-62, Jan 2016.

Y. Qian, L. Shi, and Z. Luo, "Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy," Front Med (Lausanne), vol. 7, p. 612393, 2020.

A. Acha-Sagredo et al., "Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis," Br J Cancer, vol. 122, no. 7, pp. 1050-1058, Mar 2020.

B. Wang et al., "Overexpression of Long Non-Coding RNA HOTAIR Promotes Tumor Growth and Metastasis in Human Osteosarcoma," Mol Cells, vol. 38, no. 5, pp. 432-40, May 2015.

X. Sun et al., "Long non-coding RNA HOTAIR regulates cyclin J via inhibition of microRNA-205 expression in bladder cancer," Cell Death Dis, vol. 6, no. 10, p. e1907, Oct 15 2015.

S. Biswas et al., "The Long Non-Coding RNA HOTAIR Is a Critical Epigenetic Mediator of Angiogenesis in Diabetic Retinopathy," Invest Ophthalmol Vis Sci, vol. 62, no. 3, p. 20, Mar 1 2021.

M. Lee et al., "The long non-coding RNA HOTAIR increases tumour growth and invasion in cervical cancer by targeting the Notch pathway," Oncotarget, vol. 7, no. 28, pp. 44558-44571, Jul 12 2016.

H. Mozdarani, V. Ezzatizadeh, and R. Rahbar Parvaneh, "The emerging role of the long non-coding RNA HOTAIR in breast cancer development and treatment," J Transl Med, vol. 18, no. 1, p. 152, Apr 3 2020.

S. K. Tan et al., "Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme," Mol Cancer, vol. 17, no. 1, p. 74, Mar 20 2018.

A. Rakhshan et al., "Genetic variants within ANRIL (antisense non coding RNA in the INK4 locus) are associated with risk of psoriasis," Int Immunopharmacol, vol. 78, p. 106053, Jan 2020.

B. Zhao et al., "Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-beta1/ Smad signaling pathway," Cancer Biomark, vol. 21, no. 3, pp. 613-620, Feb 14 2018.

N. Lou, G. Liu, and Y. Pan, "Long noncoding RNA ANRIL as a novel biomarker in human cancer," Future Oncol, vol. 16, no. 35, pp. 2981-2995, Dec 2020.

F. T. Liu et al., "Long noncoding RNA ANRIL: a potential novel prognostic marker in cancer: a meta-analysis," Minerva Med, vol. 107, no. 2, pp. 77-83, Apr 2016.

C. Xu, M. Yang, J. Tian, X. Wang, and Z. Li, "MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis," Int J Oncol, vol. 39, no. 1, pp. 169-75, Jul 2011.

F. Wang et al., "Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer," Oncotarget, vol. 5, no. 22, pp. 11091-102, Nov 30 2014.

C. Liu et al., "MALAT-1 is Associated with the Doxorubicin Resistance in U-2OS Osteosarcoma Cells," Cancer Manag Res, vol. 13, pp. 6879-6889, 2021.

A. Nissan et al., "Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues," Int J Cancer, vol. 130, no. 7, pp. 1598-606, Apr 1 2012.

R. Pirlog, R. Drula, A. Nutu, G. A. Calin, and I. Berindan-Neagoe, "The Roles of the Colon Cancer Associated Transcript 2 (CCAT2) Long Non-Coding RNA in Cancer: A Comprehensive Characterization of the Tumorigenic and Molecular Functions," Int J Mol Sci, vol. 22, no. 22, Nov 19 2021.

D. Zhou, J. Gu, Y. Wang, B. Luo, M. Feng, and X. Wang, "Long noncoding RNA CCAT2 reduces chemosensitivity to 5-fluorouracil in breast cancer cells by activating the mTOR axis," J Cell Mol Med, vol. 26, no. 5, pp. 1392-1401, Mar 2022.




How to Cite

Ceylan, H. (2023). Non-coding RNAs and Their Use in Cancer Diagnosis and Treatment. International Conference on Frontiers in Academic Research, 1, 285–289. Retrieved from